Transfusion-transmitted infection in hemophilia in developing countries.
Treatment of patients with bleeding disorders (especially those with hemophilia) with blood products has been associated with infections with blood-borne viruses. Of these, hepatitis B and C viruses (HBV and HCV, respectively) and the human immunodeficiency virus (HIV) have created major health problems. Although virus-inactivation procedures have virtually eliminated these viruses from newer factor concentrates since 1985, the risk remains in developing countries where there is no ready access to these concentrates. Although a few of these countries have established their own fractionation facilities and in others the respective governments make concentrates available, the large majority of countries still face the problems of blood-borne infections. HCV will invariably lead to liver damage and many hemophiliacs who were exposed to the HCV virus will succumb to cirrhosis. Only approximately 10% of hemophilic patients infected with HCV will clear the infection naturally. Coinfection with HIV shortens the life expectancy. The HIV epidemic in hemophiliacs began in the mid-1980s. Patients in developed countries were especially affected because they were predominantly treated with factor concentrates that were manufactured from thousands of blood donors. Hemophiliacs in developing countries have considerably less HIV infection, although it does exist and depends largely on the source of the plasma fractions. Progress has been made not only in the purification of factor concentrates, but also in the understanding of the HIV virus and in the development of antiretroviral treatment modalities. However, there are still several challenges in delivering antiretroviral treatment that must be addressed before the full impact of these transmitted infections is known.
Yee
Thynn Thynn
TT
Haemophilia Centre and Haemostasis Unit, The Royal Free Hospital, London, United Kingdom.
Lee
Christine A
CA
D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000302:isolation & purification / Q000627:therapeutic use; D016913:Blood Component Transfusion / Q000009:adverse effects*; D003906:Developing Countries; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D014777:Virus Diseases / Q000188:drug therapy / Q000635:transmission*; D038301:Virus Inactivation
D001779:Blood Coagulation Factors